On the market for over 24 years

ETHYL ESTERS OF ALPHA-LINOLENIC ACID

The world’s first preparation with ALA ethyl esters. Developed by Dr Andrzej Vogt through an anoxic esterification process. A pure, micellar form for people who want to consciously support the body where the modern diet most often loses balance: at the intersection of Omega‑6 : Omega‑3, oxidative stress and everyday regeneration.

30+
years of research
60%
ALA content
0%
toxins
ESTRALA Pure ALA - ethyl esters of alpha-linolenic acid

Technology essence

  • The ester form supports micelle formation and convenient absorption.
  • Process carried out in an N₂ atmosphere – with emphasis on oxygen control during manufacturing.
  • Transparency direction: batch COA (PV / AV / TOTOX + control of cyanogenic compounds).

Omega‑6 : Omega‑3

Typical Western diet 16:1
Balance target 4:1

A high Omega‑6 : Omega‑3 ratio is a clear pro-inflammatory signal — the longer it persists, the harder it becomes to restore metabolic balance.

Pro-inflammatory profile greater cellular burden risk of chronic diseases
Ordering and reviews

First get to know the product, then check buyer reviews and order

We are not asking for blind trust. You can go straight to the official store or first check current customer reviews on Allegro and come back to buy when you decide that ESTRALA is the right choice for you.

EXPERTS BEHIND ESTRALA TECHNOLOGY

A Polish innovation under the patronage of distinguished scientists with many years of experience in biotechnology and medicine.

AV

DR ANDRZEJ VOGT

Creator of ESTRALA – process technologist

“52 developed technologies, 16 implemented industrially. There is no room for compromise in science.”

Prof. dr hab. Jerzy Gubernator

PROF. DR HAB. JERZY GUBERNATOR

Biotechnologist – University of Wrocław

“It’s not what you eat, but what you absorb. Ethyl esters form micelles of nanoparticle size.”

TT

PROF. DR HAB. TADEUSZ TRZISZKA

Full professor – University of Life Sciences

“ESTRALA technology is an example of Polish biotechnological thought at world level.”

Prof. dr hab. Barbara Bażanow

PROF. DR HAB. BARBARA BAŻANOW

Microbiologist – antiviral research

“Cooperation on an antiviral medicine – 12 viruses destroyed, including coronavirus.”

Dr Andrzej Vogt - creator of ESTRALA technology
Polish Patent
52 developed technologies

DR ANDRZEJ VOGT

Creator of the anoxic esterification technology

“When we give fish oil, we give end metabolites – the body has no control. When we give ALA, we give clay from which the body itself makes as much EPA and DHA as it needs. I have used it for over 10 years and I do not admit my actual age to anyone. My friends call ALA the Elixir of Youth because that’s how it works for them.”

76 YEARS OF EXPERIENCE

Specialist in chemical technology, synthesis and esterification of fatty acids

16 TECHNOLOGIES IMPLEMENTED

Industrial production in Poland and worldwide

POLISH PATENT

Patented esterification method in a nitrogen atmosphere

SCIENTIFIC COOPERATION

University of Wrocław, University of Life Sciences

Team and laboratory

Formally: company registration in Warsaw. Operationally: R&D, quality control and batch preparation in Wrocław — in the place where the creators of the preparation work every day.

R&D QC COA

15 years of iteration

DiscoveryA sample with unusual purity became the starting point for the technology.
ImprovementMany years of refining the process, stability and analytics.
StandardizationScaling with emphasis on repeatability and quality reporting.

Company registered in Warsaw. Laboratory and production in Wrocław.

ESTRALA is a company registered in Warsaw. The heart of the project — the team and the laboratory — operates in Wrocław, where the creators of the preparation live and work every day.

ESTRALA Pure ALA laboratory – quality control and research work
Warszawa — company headquarters
Wrocław — laboratory, production and quality control

Production — “less, but better”

For years the preparation was produced in short, controlled series and went mainly to the team’s close circle. This model imposed rigor: first repeatability and quality, only then broader availability.

What we document

PV AV TOTOX cyjanogeny

The COA section on the site is prepared to publish batch results (as soon as they are made available).

A story that started “by accident” — and continues to this day

About 15 years ago, during chemical research on the stability of lipid fractions, a sample with an unusual profile and surprising purity was created in the laboratory. Instead of treating it as a curiosity, the team treated it as a starting point: over the following years the process conditions, oxygen control and purification method were refined — until the form we now call ESTRALA Pure ALA.

For most of that time, production took the form of short, controlled series — the preparation went mainly to a trusted circle of the doctor’s friends and to personal use. Only when the standards of stability and repeatability had been fully established did the project emerge from “laboratory silence” and become available more widely.

R&D‑driven, not marketing‑driven

Project decisions are made “from analysis to capsule”: parameters first, narrative second.

Iterations and improvements

The version available today is the result of many years of iteration: optimization of the process, stability and purity profile.

Warsaw ↔ Wrocław

Formally Warsaw, operationally Wrocław — where the creators of the preparation work in the laboratory.

Doctor Vogt — consistency and curiosity

Despite his advanced age, he remains professionally active and works on further concepts in the spirit of responsible science.

Anecdote from the laboratory

There is a joke within the team that asking the doctor’s age is “more difficult than a purity analysis”: the doctor smiles and avoids a clear answer, and most people still consistently underestimate his age. It is not a promise — rather an image of the energy he brings to the work. For us, only one thing matters: new projects are still being created in the laboratory, and standards never grow old.

This is part of the brand’s history and team culture. For customers, the most important thing is that the technology is still being developed with the same consistency with which it was created over the years.

CHRONIC INFLAMMATION AND THE NF-κB MECHANISM

Inflammation is the body’s natural defensive response. The problem begins when it becomes chronic — destroying the body from the inside for weeks, months and even years.

A SILENT PROCESS OF CELL DESTRUCTION

In every cell there is a protein NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). At rest it is inactive. Under the influence of oxidative stress, environmental toxins or a diet rich in Omega‑6 fatty acids, it translocates to the cell nucleus and activates a cascade of inflammatory reactions.

The modern Western diet provides Omega‑6 and Omega‑3 fatty acids in a ratio of 40:1 (in the USA) or 16:1 (in Europe), while the optimal ratio is 4:1. This disproportion promotes chronic, diffuse inflammation.

LINK TO INFLAMMATORY STATES

Studies and literature reviews indicate that as many as 20–25% of cancers may be linked to chronic inflammation. That is why a long-term disturbed fat balance, oxidative stress and NF‑κB activation are not a minor detail — they create the biological background of diseases that develop over years.

Chronic inflammationcan develop silently for a long time before clear symptoms appear.
Cellular damageoxidative stress and NF‑κB activation increase the pressure on the body’s repair mechanisms.
20–25% of cancersare linked in the literature to chronic inflammation.

Markers that show inflammatory background (to discuss with your doctor)

If you want to approach the topic methodically, start with simple laboratory parameters and interpret them in the context of lifestyle.

  • hs‑CRP — a non-specific inflammatory marker
  • Lipid profile — TG, HDL, LDL, non‑HDL
  • Glukoza / HbA1c — metabolic background
  • Complete blood count + ferritin — when your doctor recommends extending the panel

How we interpret evidence on the website

We separate biochemical mechanisms from batch quality data — therefore for every claim we look for indicators and sources that can be verified.

  • Mechanism (in vitro) ≠ clinical setting (ludzie)
  • Conclusions depend on dose, time i meal (lipidy)
  • We describe fat stability through PV/AV/TOTOX (COA)
COA PV/AV/TOTOX Sources
Mechanism of inflammation - NF-κB activation in cell membranes

Where does the imbalance come from?

  • High intake of refined vegetable oils (Omega‑6) in processed foods.
  • Low intake of Omega‑3 sources in everyday meals.
  • A change in the fatty acid profile of the food chain over the decades.

Target: 4:1

Europe (often) 16:1
Direction of balance 4:1

The higher the Omega‑6 : Omega‑3 ratio, the stronger the warning signal for the body’s inflammatory balance.

A 16:1 profile is a pro-inflammatory metabolic direction that is worth reversing through everyday dietary choices.
40:1
Omega‑6:3 ratio in the US diet
4:1
Optimal ratio (Palaeolithic diet)
~1880
Agricultural revolution – cows stopped eating grass
20–25%
Cancers linked to chronic inflammation

BLOCKING NF-κB TRANSLOCATION WITH ALA ESTERS

Alpha-linolenic acid in the form of ethyl esters acts as a biochemical blocker of the inflammatory process at the molecular level.

ALA ethyl esters physically prevent the translocation of NF‑κB protein from the cytoplasm to the cell nucleus. By incorporating into cell membranes, they displace pro-inflammatory arachidonic acid (Omega-6) and restore the natural balance of fatty acids. The effect: shutting down the inflammatory cascade before it can damage cellular DNA.

NF-κB BLOCKADE

ALA esters inhibit translocation of the NF‑κB transcription factor, silencing the inflammatory signal at the level of gene expression.

RESTORATION OF THE 4:1 RATIO

Displacing arachidonic acid from cell membranes restores the physiological Omega‑6 to Omega‑3 ratio.

REPAIR OF CELL MEMBRANES

Phospholipids and ALA esters rebuild the integrity of the lipid bilayer, restoring proper intercellular communication.

PROTECTION OF GENETIC MATERIAL

Antioxidant action protects DNA from mutations caused by reactive oxygen species (ROS) and oxidative stress.

WHY ALA ESTERS AND NOT EPA/DHA FISH OILS?

The fundamental difference between a precursor (ALA) and end metabolites (EPA/DHA) — and why it matters for your body.

Fish oils provide ready-made EPA and DHA — end metabolites. The body has no control over their amount. By providing ALA esters, you supply a precursor from which the body synthesizes exactly as much EPA and DHA as it currently needs. Excess ALA is safely excreted, whereas excess EPA/DHA may be directed onto hazardous metabolic pathways.

Parameter ESTRALA (ALA esters) Fish oils (EPA/DHA)
Type of compound Biochemical classification Precursor – the body controls synthesis End metabolites – no control
Body control Homeostasis regulation Full – EPA/DHA synthesis on demand None – ready-made metabolites
Risk of overdosing Use safety None – excess excreted Possible at doses >1 g/day
Toxicological studies National Centre of Toxicology 0 effects at >12,000 mg/kg Requires dose limitation
Cancer risk Studies UK/USA/Canada No data on increased risk +40% prostate/ovarian cancer at 3–5 g/day
Cyanohydrins Toxic cyanogenic compounds 100% removed (anoxic process) Not applicable
Oxidative stability Resistance to oxidation High (production in an N₂ atmosphere) Variable – they go rancid quickly
Additional components Nutritional value Phytosterols, lignans, vit. A/D/E/K2, lecithin Only EPA/DHA
Hormonal support Phytosterols and lignans Relief of menopausal symptoms None
Source Origin of raw material Plant-based (flax) – sustainable Fish – heavy metals, overfishing
“When we give fish oil, we give end metabolites – the body has no control. When we give ALA, we give clay from which the body itself makes as much EPA and DHA as it needs. That is the fundamental difference in the approach to supplementation.”
AV
Dr Andrzej Vogt
Creator of ESTRALA technology

ESTRALA PURE ALA – ESTERIFICATION TECHNOLOGY

The world’s first preparation with ethyl esters of alpha-linolenic acid. Industrial production for over 24 years.

ESTRALA Pure ALA - product

The process in 3 steps

Raw materialPlant oils as a source of ALA (Omega‑3 precursor).
EsterificationReaction in a controlled atmosphere (N₂) and process conditions.
ControlQuality analytics + preparation of batch report (COA).

“Hard” parameters

Instead of generalities — a prepared place for publishing batch data (COA). The most important indicators for lipids:

PV AV TOTOX stability

ANOXIC ESTERIFICATION PROCESS

Traditional flaxseed oil contains valuable fatty acids trapped in large triglyceride molecules, surrounded by toxic cyanogens (linamarin, lotaustralin). Dr Vogt’s team applied esterification in a nitrogen atmosphere — a process that:

1. Breaks glycerol bonds, releasing free fatty acids.
2. Combines them with ethanol, creating small, stable ethyl esters.
3. Eliminates 100% of cyanohydrins under controlled conditions.

Result: a molecule that is smaller, more stable and micellarly bioavailable — ready for immediate absorption in the small intestine.

0% toxins

Removed cyanohydrins

Fast absorption

Small ester molecules

Stability

Production in an N₂ atmosphere

60% ALA

Highest content

STORAGE

  • Temperature 5°C (refrigerator)
  • Protect from light
  • Glass containers (not plastic)
  • Avoid contact with oxygen

THE SCIENCE BEHIND ETHYL ESTERS

Learn about the biochemical processes that occur after taking ALA esters.

Fatty acid esterification process

ANOXIC ESTERIFICATION

A process carried out in a nitrogen atmosphere (N₂) allows isolation of pure ALA while simultaneously removing 100% of cyanogenic compounds. Temperature and pressure are controlled with pharmaceutical precision.

Cellular energy - mitochondria and ATP

MITOCHONDRIAL REGENERATION

ALA esters repair mitochondrial membranes, increasing the efficiency of ATP (adenosine triphosphate) production — the main energy carrier in cells.

Micellar bioavailability of ethyl esters

MICELLAR BIOAVAILABILITY

Small ester molecules spontaneously form nanometric micelles. Absorption in the small intestine occurs without the involvement of pancreatic lipase.

Blocking NF-κB translocation

NF-κB INHIBITION

ALA incorporated into cell membranes physically blocks translocation of the NF‑κB transcription factor, inhibiting expression of pro-inflammatory genes (IL-1β, IL-6, TNF-α).

RESULTS OF CLINICAL AND PRECLINICAL STUDIES

We bring together scientific literature, quality standards and the reporting plan (COA) to distinguish biochemical mechanisms from hard batch-control data.

LIPID SAFETY AND STABILITY

In lipids, oxidation is crucial. That is why anoxic technology (N₂) is combined with reporting of stability indicators (PV/AV/TOTOX) and control of raw-material purity.

PV / AV / TOTOX
Stability reporting standard (COA)

ALA – MECHANISMS IN THE LITERATURE

Studies describe the influence of ALA and omega‑3 on inflammatory signalling (including NF‑κB pathways) and lipid metabolism. On the website we collect bibliography and clearly mark the level of evidence.

NF‑κB
Signalling pathway often analysed in publications

ETHYL ESTER FORM (EE)

The literature compares the bioavailability of different omega‑3 forms (EE, TAG, PL). Results depend on the protocol, dose and the presence of fat in the meal — which is why at ESTRALA we focus on transparent methods and batch documentation.

EE vs TAG
Comparisons of forms in scientific reviews

TOXICOLOGICAL STUDIES

The National Centre of Toxicology conducted comprehensive safety studies of ALA ethyl esters. Result: no acute or chronic toxicity even at extreme doses.

>12 000 mg/kg
Dose without side effects

CARDIOVASCULAR REGENERATION

Studies in rats after experimental myocardial infarction showed full recovery of performance within 3–4 weeks with ALA ester supplementation.

-30%
Atherogenicity index

TYPE 2 DIABETES

Clinical studies observed normalization of glucose levels in patients with type 2 diabetes. A drop in glycaemia from 300–320 mg/dl to 115–120 mg/dl.

~60%
Reduction in glycaemia in 6–8 weeks

DR VOGT’S PRECLINICAL STUDIES

Note: The information below concerns only preclinical studies (on animals) conducted by Dr Andrzej Vogt. The ESTRALA preparation has not been clinically studied in oncology and no human studies have been conducted in this area.

As part of preclinical research, Dr Vogt observed the effect of ALA esters on animal models. The results of these preliminary studies are promising from the point of view of further research directions, however they do not constitute a basis for formulating claims about the product’s medicinal effect.

ESTRALA Pure ALA is a food supplement that may support the body’s proper functioning. It is not a medicine and does not replace oncological treatment. People with cancer should always consult supplementation with their attending physician.

Scientific basis and bibliography

We are expanding the website with increasingly precise sources. Below you will find selected publications and reference documents concerning ALA, the Omega‑6/Omega‑3 balance and inflammatory processes. This is general literature — it is not a study of a specific product.

mechanism preclinical clinical reference document

ALA – authorised EU position (EFSA)

The European Food Safety Authority (EFSA) assessed the evidence for ALA, among others in the context of maintaining normal blood cholesterol levels (scientific opinion, Article 13).

Ethyl ester form – bioavailability reviews

The literature compares the bioavailability of omega‑3 in the form of ethyl esters (EE), triglycerides (TAG) and other forms. Conclusions depend on the protocol and concurrent fat intake.

Omega‑3, inflammation and NF‑κB pathways

The literature describes the effect of omega‑3 fatty acids on inflammatory mediators and the expression of genes related to the immune response.

How should evidence be read? Precision means distinction: mechanism (in vitro) ≠ preclinical study ≠ observation ≠ clinical study. The publications above provide scientific context for discussion of ALA and omega‑3 — they are not direct confirmation of the effect of a specific product.

BATCH CONTROL, STABILITY AND DATA TRANSPARENCY

We are expanding the service with increasingly precise quality data. Below we show the reporting standard (COA / protocols) — so that each batch is described by parameters, not slogans.

What we measure (COA framework)

Parameters and methods vary depending on the raw material and the process. Below is an example set of fields that we ultimately publish for a batch (in the form of a COA document):

  • ALA ethyl ester profile — chromatography (e.g. GC‑FID/GC‑MS) + peak identification
  • Lipid oxidation — PV / AV / TOTOX (freshness and stability indicators)
  • Solvents and process residues — limits and compliance with standards
  • Heavy metals — Pb, Cd, Hg, As (ICP methods)
  • Microbiology — microbiological safety (depending on form and packaging)
  • Water / water activity — parameters affecting stability

Why is this important? For fats, oxidation control is crucial. That is why at ESTRALA we place emphasis on oxygen control in the process and on reporting stability indicators.

Diagram: oxygen vs stability (illustrative)

The chart below is an illustrative diagram, showing the relationship: less oxygen in the process and storage → greater lipid stability. It is not the result of a specific batch study.

Ultimately: COA for each batch

This place is prepared for publication of a PDF “Certificate of Analysis” for each series (after the publication process is implemented).

How to read a COA?

MULTIDIRECTIONAL ACTION OF ALA ESTERS

Ethyl esters of alpha-linolenic acid support the proper functioning of many body systems.

ESTRALA benefits - brain, muscles, DNA

COGNITIVE FUNCTIONS

Supports proper brain function and cognitive processes

CARDIOVASCULAR SYSTEM

Supports vessel elasticity and a proper lipid profile

MUSCLE REGENERATION

Accelerates rebuilding of muscle fibres after effort

IMMUNITY

Supports proper functioning of the immune system

HORMONAL SUPPORT

Phytosterols and lignans relieve menopausal symptoms

METABOLISM

Supports proper metabolism and weight control

SKIN AND HAIR

Repair of cell membranes improves skin condition

CELLULAR REGENERATION

Rebuilding membranes and protecting genetic material

PROTECTION AT EVERY STAGE OF LIFE

ESTRALA supports children’s development, the vitality of young adults and the health of seniors

CHILDREN
YOUNG ADULTS
SENIORS
ESTRALA for children - brain development and concentration

SUPPORT FOR YOUR CHILD’S DEVELOPMENT

A child’s brain develops intensively and needs the right ingredients. ESTRALA provides the precursor of DHA — a key building fat for the brain and eyes. Omega‑3 fatty acids support proper cognitive development and help with concentration and learning.

Supports development of the brain and nervous system
Facilitates concentration and learning
Supports visual development
Reduces the risk of allergies
Calms and helps regulate emotions
Supports proper speech development

Priorities

  • Development of the nervous system and cognitive functions.
  • Support for lipid balance in the diet.
  • Simple, repeatable habits (regularity).

How to read the site

In the sections “Studies”, “Sources” and “Quality control (COA)” we separate biochemical mechanisms from batch quality data — so that communication is as transparent as possible.

HOW TO USE ESTRALA?

Simple dosing for maximum health benefits

RECOMMENDED DAILY DOSE

10ml
once daily, in one serving

WHEN TO TAKE

During a meal or right after eating

BOTTLE EFFICIENCY

25
days of use from one 250 ml bottle

ESTRALA works reparatively — it rebuilds damaged cell membranes. You will notice the first effects after a few weeks of regular use. For full health benefits we recommend a minimum of 3 months of regular use.

FREQUENTLY ASKED QUESTIONS

Answers to the questions that may be on your mind

Who is Dr Andrzej Vogt and why trust him?
+
Dr Andrzej Vogt is an outstanding Polish scientist with more than 30 years of experience in chemical technology and organic synthesis. Associated with FLC Pharma and the University of Wrocław, he developed a breakthrough anaerobic esterification method. His work has been published in reputable scientific journals such as “Przemysł Chemiczny”.
How long does one bottle of ESTRALA last?
+
One 250 ml bottle lasts about 25 days at the recommended dosage of 10 ml per day. For the best health benefits we recommend regular use for a minimum of 3 months.
Is ESTRALA safe for children?
+
Yes! ESTRALA is completely safe for children. The preparation does not contain toxins, heavy metals or harmful substances — as confirmed by laboratory tests. For children we recommend a reduced dosage adapted to age and weight.
How is ESTRALA different from regular flaxseed oil?
+
ESTRALA is ethyl esters of alpha-linolenic acid — a chemically processed and purified form. Unlike flaxseed oil, it does not contain toxic cyanohydrins, it is stable (does not go rancid), it has much better bioavailability thanks to small molecules and it does not burden the liver with the emulsification process.
When will I notice the first effects?
+
The first effects may be visible after 2–3 weeks of regular use. Full health benefits — regeneration of cell membranes, improvement of lipid profile, reduction of inflammatory states — usually appear after 2–3 months of systematic use.
How should ESTRALA be stored?
+
Store in the refrigerator after opening. Before opening it may be kept at room temperature, away from sunlight. Use within 30 days after opening. Thanks to production in a nitrogen atmosphere, ESTRALA is much more stable than traditional oils.

DO YOU HAVE QUESTIONS? CONTACT US

We will be happy to answer questions about the product, technology and cooperation opportunities.

CONTACT DETAILS

We are available Monday to Friday from 9:00 am to 5:00 pm. We respond to messages within 24 hours.

Manufacturer: Estrala Sp. z o.o.
Polska

FOLLOW US